Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
MENU
Back to Top

Imaging and Biomarkers Workshop

The use of neuroimaging and other biomarkers in those with suspected dementia has radically changed over the last decade, from that of simply ruling out other organic causes of cognitive decline, to providing important information to positively support the differential diagnosis of the main subtypes of dementia, especially at the early stages. Their use has also extended to application as surrogate outcome markers for clinical trials, especially those aimed at disease modification. Modalities currently in clinical use include CT, MRI, Perfusion SPECT, Glucose (FDG) PET, Dopaminergic (FP-CIT) SPECT or PET and Amyloid PET, though not all modalities are either available or reimbursed in all countries. CSF biomarkers are used clinically in some centres, whilst novel biomarkers, currently only for research applications, include Tau PET imaging and blood biomarkers.

This workshop is run by internationally recognised experts in the developing and clinical use of imaging and biomarkers for dementia. The workshop will provide a state of the art summary of the use of structural (CT and MR) imaging, perfusion and dopaminergic SPECT, FDG (metabolic) and amyloid PET and CSF biomarkers. Clinical and diagnostic guidelines incorporating such biomarkers will be summarised. This will be a very interactive workshop, with several opportunities to rate scans and discuss the application of biomarkers with the experts. In particular, we will include a session on the rating of medial temporal atrophy from CT or MR scans, which will be of considerable practical use to all those involved with assessing and diagnosing people with suspected dementia.

The aim is that those attending will become more familiar with which imaging modalities and biomarkers are available, when they might best be used clinically, and to gain skills and confidence in interpreting scans, most especially in relation to the presence or absence of medial temporal lobe atrophy.

Dr Ron Shnier: Structural imaging: CT and MR How images are formed and what they can show
Prof John O'Brien:  Practical Use of MR Imaging: How to Rate Medial Temporal Atrophy
Prof John O'Brien:  Perfusion and dopaminergic SPECT
Prof Christopher Rowe:  Use of FDG (metabolic) PET
Prof Christopher Rowe:  Amyloid and newer PET methods
Prof Colin Masters:  Imaging, blood and CSF biomarkers and their use to track disease progression

Acknowledgements

Acadia Pharmaceuticals Otsuka Pharmaceuticals Cambridge University Press Avanir Pharmaceuticals
CORPORATE COUNCILS

IPA

555 E. Wells St.
Suite 1100
Milwaukee, WI 53202
United States

Tel: +1.414.918.9889
Fax: +1.414.276.3349
E-mail: info@ipa-online.org

IPA Briefs

Sign up for IPA Briefs and receive the latest announcements from IPA.

© International Psychogeriatric Association. All rights reserved.